Development Disorders

Main Content

fliGHt

Study title

Multi-center, phase 3, open label, 26-week trial investigating the safety, tolerability, and efficacy of Transcon hGH administered once weekly in children with growth hormone deficiency

  • Principal Investigator: Dr. Naznin Dixit

Purpose

This study will assess safety and tolerability of an experimental drug in children with growth hormone deficiency (GHD).

Who can participate

Those eligible to participate in this study include:

  • Children ages 3-17 diagnosed with growth hormone deficiency (GHD)

For more information

  • Deepali Bhatt
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 815-9481
  • IRB Number: 2017-0267